Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance

Executive Summary

FDA plans to address the use of computer simulation models in an upcoming guidance on issues firms should consider at the end of Phase IIa

You may also be interested in...

FDA Pharmacogenomics Data Guidance To Be Finalized Later This Year

FDA will not issue a final guidance on pharmacogenomic data submissions until later this year, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, told the Biotechnology Industry Organization annual meeting in San Francisco June 8

FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs

FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said

FDA Will Begin End-Of-Phase IIa Meetings Prior To January Guidance

FDA will begin a pilot program for end-of-Phase IIa meetings in advance of a draft guidance expected to be issued in early 2004




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts